Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Moleculin Biotech (MBRX) Stock Price

News articles about Moleculin Biotech (NASDAQ:MBRX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Moleculin Biotech earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.6750854852111 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Moleculin Biotech (MBRX) traded down $0.05 during trading on Tuesday, reaching $1.82. The company’s stock had a trading volume of 98,571 shares, compared to its average volume of 170,933. The stock has a market capitalization of $38.35 and a price-to-earnings ratio of -3.87. Moleculin Biotech has a fifty-two week low of $0.71 and a fifty-two week high of $3.75.

Moleculin Biotech (NASDAQ:MBRX) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($0.14) EPS for the quarter. sell-side analysts forecast that Moleculin Biotech will post -0.47 earnings per share for the current fiscal year.

Separately, Roth Capital began coverage on Moleculin Biotech in a research note on Wednesday, December 20th. They issued a “buy” rating and a $8.00 price target for the company.

COPYRIGHT VIOLATION WARNING: This report was originally published by BBNS and is the property of of BBNS. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://baseballnewssource.com/markets/moleculin-biotech-mbrx-receiving-somewhat-positive-media-coverage-analysis-finds/1820948.html.

About Moleculin Biotech

Moleculin Biotech, Inc is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).

Insider Buying and Selling by Quarter for Moleculin Biotech (NASDAQ:MBRX)

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.